Cost Consequences of the 340B Drug Discount Program - Drug Pricing Lab

Cost Consequences of the 340B Drug Discount Program

The Journal of the American Medical Association
May 15, 2013

Drs. Rena Conti and Peter Bach report on the unintended consequences of the 340B drug discount program, which may alter physician prescribing habits, widen the disparity in hospital profits, and increase list prices of drugs to compensate for revenue losses.

Read Full Article Here